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The United Kingdom (UK) Facioscapulohumeral Dystro-
phy (FSHD) Patient Registry launched in May 2013.
Funded by the Muscular Dystrophy Campaign and sup-
ported by the TREAT-NMD Alliance. This patient driven
registry collects the internationally agreed core dataset, an
outcome of an ENMC Workshop held in 2010 [1],
through a novel online portal (http://www.fshd-registry.
org/uk). Genetic details are added by a nominated neuro-
muscular specialist. In addition questionnaires about pain,
quality of life and scapular fixation are included.
In the 12 months between May 2013 and May 2014 over
400 people registered, 92% with a diagnosis of FSHD1.
Similar proportions of patients registered from both sexes
and 59% of patients were between 40 and 70 years old
(mean 47.39). Muscle weakness was widely reported with
periscapular shoulder weakness occurring most frequently
(89%) followed by weakness of the hip girdle (73%), facial
muscles (72%) and foot dorsiflexor (71%). The onset of
facial weakness was reported significantly earlier than
weakness in other areas with 66% experiencing facial
weakness before 20 years old.
Full time wheelchair use was reported in 18% of cases,
62% having lost ambulation between 31 and 60 years
old (mean 41.61). Use of a wheelchair or other assistive
device part time was reported in 44% of cases. A small
proportion of patients report hearing loss (18%), retinal
vascular disease (2%) and using ventilation (7%).
Additional questionnaires on pain were completed by
350 patients during this time and the majority reporting
at least some pain, most often described as tiring or
aching. Persistent pain (experienced for at least 3 months
in a year) was reported by 92% with 53% of people
describing this pain as distressing, horrible or excruciat-
ing. The location of the pain is variable but most often
reported in the shoulder.
A broad spectrum of patients has registered providing
a new insight into the FSHD population in the UK. The
Registry aims to help facilitate and accelerate clinical
research and trials, sharing a common dataset with a
growing number of FSHD registries around the world
will allow the registry to achieve this locally and interna-
tionally. The registry is well placed to inform future
clinical research and help develop of standards of care.
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